tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Revolution Medicines initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $67 price target The firm believes daraxonrasib’s mechanism of action is “de-risked” in pancreatic ductal adenocarcinoma and second-line non-small cell lung cancer. A positive readout for the RASolute302 trial, expected in 2026, is a high probability, the analyst tells investors in a research note. Wells likes the setup for Revolution shares over the next 12-18 months.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1